A Randomized, Double-blind, Parallel Group, Multicenter, Stratified Study Evaluating the Efficacy and Safety of Repeat Doses of GSK3772847 Compared With Placebo in Participants With Moderately Severe Asthma
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 11 Sep 2017
At a glance
- Drugs GSK3772847 (Primary) ; Fluticasone propionate; Salmeterol/fluticasone propionate
- Indications Asthma
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 06 Sep 2017 Planned initiation date changed from 31 Aug 2017 to 8 Sep 2017.
- 25 Aug 2017 Planned End Date changed from 25 Oct 2018 to 8 Nov 2018.
- 25 Aug 2017 Planned primary completion date changed from 2 Aug 2018 to 16 Aug 2018.